UCB (UCBJY) News Today $91.17 +1.50 (+1.67%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartDividendFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period UCB (OTC:UCBJY) Stock Quotes, Forecast and News SummaryNovember 22 at 6:25 AM | benzinga.comFDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin DiseaseNovember 20 at 3:39 PM | benzinga.comBiogen, UCB release phase 3 data on lupus candidate dapirolizumabNovember 19 at 2:24 PM | msn.comUCB (OTCMKTS:UCBJY) Sets New 12-Month High - What's Next?UCB (OTCMKTS:UCBJY) Sets New 1-Year High - Still a Buy?November 5, 2024 | marketbeat.comOruka draws buy at Stifel on potential against psoriasisOctober 11, 2024 | msn.comUCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024September 26, 2024 | finance.yahoo.comBiogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal TrialSeptember 24, 2024 | finance.yahoo.comUCB gets expanded FDA approval for psoriasis drug BimzelxSeptember 23, 2024 | seekingalpha.comUCB United Community Banks, Inc.August 29, 2024 | seekingalpha.comBarclays Sticks to Its Buy Rating for UCB SA (0NZT)August 28, 2024 | markets.businessinsider.comBelgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management CompaniesAugust 26, 2024 | msn.comDAY BY DAY Upgrades UCB SA - Depositary Receipt () (UCBJY)August 12, 2024 | msn.comBarclays Remains a Buy on UCB SA (0NZT)July 29, 2024 | markets.businessinsider.comUBS Keeps Their Buy Rating on UCB SA (0NZT)July 26, 2024 | markets.businessinsider.comUCB SA's Dividend AnalysisApril 25, 2024 | finance.yahoo.comDrugmakers reportedly planning to raise prices on 500+ drugs in January (update)December 29, 2023 | seekingalpha.comDrugmakers reportedly planning to raise prices on 500+ drugs in JanuaryDecember 29, 2023 | msn.comFDA’s new drug approvals for 2023 rise 51% from last yearDecember 28, 2023 | msn.comUCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual MeetingDecember 1, 2023 | finance.yahoo.comUCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque PsoriasisNovember 14, 2023 | finance.yahoo.comFDA approves UCB's Bimzelx for plaque psoriasisOctober 18, 2023 | msn.comUCB presents late-breaking posters at Child Neurology Society MeetingOctober 4, 2023 | benzinga.comEMA advisors recommend many new meds at latest meetingSeptember 15, 2023 | msn.comSkin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst AssertsAugust 31, 2023 | markets.businessinsider.comCrohn's disease drugmakers set to benefit from expected rise in casesAugust 26, 2023 | msn.comUCB (UCBJY) Declares $0.73 DividendApril 13, 2023 | msn.comUnited Commercial Bank Ltd.April 6, 2023 | wsj.comBimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 WeeksMarch 20, 2023 | benzinga.comUCB SA (UCBJY) Stock Historical Prices & Data - Yahoo FinanceDecember 23, 2022 | finance.yahoo.comUCB drug meets main goals of 2 phase 3 trials for painful skin disorderDecember 9, 2022 | seekingalpha.comUCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022November 8, 2022 | benzinga.comUCB presents latest data from generalized myasthenia gravis portfolio at AANEM meetingSeptember 24, 2022 | benzinga.comUCB SA (UCB.BR)September 22, 2022 | finance.yahoo.comUCB.BR - UCB SA | Stock Price & Latest News | ReutersSeptember 17, 2022 | reuters.comUCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV CongressSeptember 2, 2022 | benzinga.comUCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravisMay 11, 2022 | finance.yahoo.comJAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)May 4, 2022 | markets.businessinsider.comFINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)March 29, 2022 | markets.businessinsider.comUCB's Rare Childhood Epilepsy Drug Scores FDA ApprovalMarch 28, 2022 | finance.yahoo.comUCB's Fintepla gets FDA approval to treat rare childhood epilepsyMarch 28, 2022 | seekingalpha.comUCB completes $1.9B acquisition of ZogenixMarch 7, 2022 | seekingalpha.comZogenix Surges After UCB's $1.9B Acquisition OfferJanuary 21, 2022 | ca.finance.yahoo.comUCB says second late-stage psoriatic arthritis trial for bimekizumab met main goalJanuary 21, 2022 | seekingalpha.comPositive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis StudyJanuary 20, 2022 | markets.businessinsider.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Zogenix, Inc. MergerJanuary 20, 2022 | apnews.comPositive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis TrialDecember 18, 2021 | markets.businessinsider.comUCBJY Real-Time QuotesDecember 18, 2021 | nasdaq.comUpdate on U.S. FDA Review of Biologics License Application (BLA) for bimekizumabOctober 16, 2021 | finance.yahoo.comUCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and OlderAugust 30, 2021 | finance.yahoo.com Get UCB News Delivered to You Automatically Sign up to receive the latest news and ratings for UCBJY and its competitors with MarketBeat's FREE daily newsletter. Email Address With the “Bitcoin Loophole” you can help supercharge the gains by 10x or more! (Ad)You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet! >> Tap here to sign up and join them for the imminent workshop UCBJY Media Mentions By Week UCBJY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UCBJY News Sentiment▼-0.050.48▲Average Medical News Sentiment UCBJY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UCBJY Articles This Week▼30▲UCBJY Articles Average Week Get UCB News Delivered to You Automatically Sign up to receive the latest news and ratings for UCBJY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNY News Today BMY News Today VRTX News Today CSLLY News Today REGN News Today ZTS News Today GSK News Today TAK News Today UCBJF News Today ALNY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:UCBJY) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBREAKING: NVDA loses $175 billion in 8 minutesIt's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, w...Chaikin Analytics | SponsoredFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Share UCB With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
